OPKO Health, Inc. (0KCS.L)
USD 1.63
(0.62%)
USD 1.63
(0.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.01 Billion USD | -7.18% |
| 2022 | 2.16 Billion USD | -9.68% |
| 2021 | 2.39 Billion USD | -2.97% |
| 2020 | 2.47 Billion USD | 7.09% |
| 2019 | 2.3 Billion USD | -5.79% |
| 2018 | 2.45 Billion USD | -5.36% |
| 2017 | 2.58 Billion USD | -6.38% |
| 2016 | 2.76 Billion USD | -1.18% |
| 2015 | 2.79 Billion USD | 120.84% |
| 2014 | 1.26 Billion USD | -8.9% |
| 2013 | 1.39 Billion USD | 380.11% |
| 2012 | 289.83 Million USD | 26.29% |
| 2011 | 229.48 Million USD | 194.8% |
| 2010 | 77.84 Million USD | -10.96% |
| 2009 | 87.43 Million USD | 301.72% |
| 2008 | 21.76 Million USD | -45.0% |
| 2007 | 39.56 Million USD | 352.1% |
| 2006 | 8.75 Million USD | -2.76% |
| 2005 | 9 Million USD | -10.63% |
| 2004 | 10.07 Million USD | -11.21% |
| 2003 | 11.34 Million USD | -35.24% |
| 2002 | 17.51 Million USD | -36.6% |
| 2001 | 27.62 Million USD | -26.09% |
| 2000 | 37.37 Million USD | 732.29% |
| 1999 | 4.49 Million USD | -41.68% |
| 1998 | 7.7 Million USD | 175.0% |
| 1997 | 2.8 Million USD | -28.21% |
| 1996 | 3.9 Million USD | -40.0% |
| 1995 | 6.5 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.97 Billion USD | 0.3% |
| 2024 Q1 | 1.97 Billion USD | -1.87% |
| 2023 Q3 | 2.05 Billion USD | -4.73% |
| 2023 Q1 | 2.16 Billion USD | 0.11% |
| 2023 Q4 | 2.01 Billion USD | -2.19% |
| 2023 Q2 | 2.15 Billion USD | -0.49% |
| 2023 FY | 2.01 Billion USD | -7.18% |
| 2022 Q1 | 2.3 Billion USD | -3.87% |
| 2022 Q4 | 2.16 Billion USD | -2.58% |
| 2022 FY | 2.16 Billion USD | -9.68% |
| 2022 Q3 | 2.22 Billion USD | -6.11% |
| 2022 Q2 | 2.36 Billion USD | 2.72% |
| 2021 Q1 | 2.51 Billion USD | 1.88% |
| 2021 FY | 2.39 Billion USD | -2.97% |
| 2021 Q2 | 2.42 Billion USD | -3.89% |
| 2021 Q4 | 2.39 Billion USD | -0.74% |
| 2021 Q3 | 2.41 Billion USD | -0.17% |
| 2020 Q2 | 2.32 Billion USD | 4.08% |
| 2020 Q3 | 2.37 Billion USD | 2.05% |
| 2020 Q4 | 2.47 Billion USD | 4.29% |
| 2020 FY | 2.47 Billion USD | 7.09% |
| 2020 Q1 | 2.23 Billion USD | -3.32% |
| 2019 Q4 | 2.3 Billion USD | -2.54% |
| 2019 Q3 | 2.36 Billion USD | -3.53% |
| 2019 Q2 | 2.45 Billion USD | -4.62% |
| 2019 FY | 2.3 Billion USD | -5.79% |
| 2019 Q1 | 2.57 Billion USD | 5.07% |
| 2018 Q3 | 2.48 Billion USD | -1.97% |
| 2018 FY | 2.45 Billion USD | -5.36% |
| 2018 Q4 | 2.45 Billion USD | -1.2% |
| 2018 Q2 | 2.53 Billion USD | -1.86% |
| 2018 Q1 | 2.57 Billion USD | -0.43% |
| 2017 Q2 | 2.76 Billion USD | 0.31% |
| 2017 Q1 | 2.76 Billion USD | -0.24% |
| 2017 Q3 | 2.72 Billion USD | -1.69% |
| 2017 FY | 2.58 Billion USD | -6.38% |
| 2017 Q4 | 2.58 Billion USD | -4.85% |
| 2016 Q2 | 2.77 Billion USD | -0.69% |
| 2016 FY | 2.76 Billion USD | -1.18% |
| 2016 Q3 | 2.8 Billion USD | 0.94% |
| 2016 Q4 | 2.76 Billion USD | -1.19% |
| 2016 Q1 | 2.79 Billion USD | -0.23% |
| 2015 Q2 | 1.52 Billion USD | 0.88% |
| 2015 Q1 | 1.51 Billion USD | 19.29% |
| 2015 Q3 | 3.01 Billion USD | 97.7% |
| 2015 Q4 | 2.79 Billion USD | -7.17% |
| 2015 FY | 2.79 Billion USD | 120.84% |
| 2014 FY | 1.26 Billion USD | -8.9% |
| 2014 Q1 | 1.35 Billion USD | -2.57% |
| 2014 Q2 | 1.32 Billion USD | -2.11% |
| 2014 Q4 | 1.26 Billion USD | -2.13% |
| 2014 Q3 | 1.29 Billion USD | -2.4% |
| 2013 FY | 1.39 Billion USD | 380.11% |
| 2013 Q2 | 641.08 Million USD | -1.97% |
| 2013 Q1 | 653.93 Million USD | 125.63% |
| 2013 Q3 | 1.38 Billion USD | 115.73% |
| 2013 Q4 | 1.39 Billion USD | 0.62% |
| 2012 Q3 | 250.02 Million USD | 8.48% |
| 2012 Q1 | 231.57 Million USD | 0.91% |
| 2012 FY | 289.83 Million USD | 26.29% |
| 2012 Q2 | 230.47 Million USD | -0.47% |
| 2012 Q4 | 289.83 Million USD | 15.92% |
| 2011 FY | 229.48 Million USD | 194.8% |
| 2011 Q4 | 229.48 Million USD | 51.98% |
| 2011 Q3 | 151 Million USD | -5.87% |
| 2011 Q2 | 160.41 Million USD | -9.01% |
| 2011 Q1 | 176.3 Million USD | 126.48% |
| 2010 Q3 | 67.83 Million USD | -0.27% |
| 2010 Q2 | 68.01 Million USD | -21.73% |
| 2010 Q1 | 86.9 Million USD | -0.6% |
| 2010 Q4 | 77.84 Million USD | 14.76% |
| 2010 FY | 77.84 Million USD | -10.96% |
| 2009 Q2 | 59.7 Million USD | 211.84% |
| 2009 Q3 | 83.6 Million USD | 40.03% |
| 2009 Q4 | 87.43 Million USD | 4.58% |
| 2009 FY | 87.43 Million USD | 301.72% |
| 2009 Q1 | 19.14 Million USD | -12.03% |
| 2008 Q1 | 30.82 Million USD | -22.1% |
| 2008 Q2 | 20.91 Million USD | -32.16% |
| 2008 Q4 | 21.76 Million USD | -26.99% |
| 2008 FY | 21.76 Million USD | -45.0% |
| 2008 Q3 | 29.8 Million USD | 42.54% |
| 2007 Q1 | 17.47 Million USD | 99.63% |
| 2007 Q4 | 39.56 Million USD | 264.38% |
| 2007 FY | 39.56 Million USD | 352.1% |
| 2007 Q3 | 10.85 Million USD | -7.6% |
| 2007 Q2 | 11.75 Million USD | -32.74% |
| 2006 Q4 | 8.75 Million USD | -0.86% |
| 2006 Q1 | 8.98 Million USD | -0.18% |
| 2006 FY | 8.75 Million USD | -2.76% |
| 2006 Q2 | 8.87 Million USD | -1.21% |
| 2006 Q3 | 8.82 Million USD | -0.53% |
| 2005 Q1 | 9.64 Million USD | -4.24% |
| 2005 FY | 9 Million USD | -10.63% |
| 2005 Q4 | 9 Million USD | -1.43% |
| 2005 Q3 | 9.13 Million USD | -2.31% |
| 2005 Q2 | 9.34 Million USD | -3.08% |
| 2004 Q1 | 10.03 Million USD | -11.54% |
| 2004 Q2 | 9.59 Million USD | -4.38% |
| 2004 Q4 | 10.07 Million USD | 8.85% |
| 2004 FY | 10.07 Million USD | -11.21% |
| 2004 Q3 | 9.25 Million USD | -3.56% |
| 2003 FY | 11.34 Million USD | -35.24% |
| 2003 Q3 | 12.47 Million USD | -12.66% |
| 2003 Q1 | 15.94 Million USD | -8.95% |
| 2003 Q4 | 11.34 Million USD | -9.05% |
| 2003 Q2 | 14.27 Million USD | -10.47% |
| 2002 Q4 | 17.51 Million USD | -17.06% |
| 2002 FY | 17.51 Million USD | -36.6% |
| 2002 Q1 | 25.83 Million USD | -6.47% |
| 2002 Q2 | 23.66 Million USD | -8.41% |
| 2002 Q3 | 21.11 Million USD | -10.77% |
| 2001 FY | 27.62 Million USD | -26.09% |
| 2001 Q4 | 27.62 Million USD | -12.6% |
| 2001 Q3 | 31.6 Million USD | -4.16% |
| 2001 Q2 | 32.97 Million USD | -7.87% |
| 2001 Q1 | 35.79 Million USD | -4.24% |
| 2000 Q2 | 40.1 Million USD | 117.8% |
| 2000 Q3 | 38.41 Million USD | -4.21% |
| 2000 Q4 | 37.37 Million USD | -2.69% |
| 2000 FY | 37.37 Million USD | 732.29% |
| 2000 Q1 | 18.41 Million USD | 309.95% |
| 1999 Q2 | 6.3 Million USD | -16.0% |
| 1999 Q4 | 4.49 Million USD | -22.57% |
| 1999 FY | 4.49 Million USD | -41.68% |
| 1999 Q1 | 7.5 Million USD | -2.6% |
| 1999 Q3 | 5.8 Million USD | -7.94% |
| 1998 Q4 | 7.7 Million USD | -12.5% |
| 1998 FY | 7.7 Million USD | 175.0% |
| 1998 Q1 | 2.1 Million USD | -25.0% |
| 1998 Q2 | 10 Million USD | 376.19% |
| 1998 Q3 | 8.8 Million USD | -12.0% |
| 1997 Q2 | 2.8 Million USD | -24.32% |
| 1997 Q1 | 3.7 Million USD | -5.13% |
| 1997 Q3 | 2.1 Million USD | -25.0% |
| 1997 FY | 2.8 Million USD | -28.21% |
| 1997 Q4 | 2.8 Million USD | 33.33% |
| 1996 Q3 | 4.8 Million USD | -11.11% |
| 1996 Q4 | 3.9 Million USD | -18.75% |
| 1996 Q2 | 5.4 Million USD | -8.47% |
| 1996 Q1 | 5.9 Million USD | 0.0% |
| 1996 FY | 3.9 Million USD | -40.0% |
| 1995 FY | 6.5 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -303.022% |
| Dynavax Technologies Corporation | 997.09 Million USD | -101.756% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -42.777% |
| Perrigo Company plc | 10.8 Billion USD | 81.389% |
| Illumina, Inc. | 10.11 Billion USD | 80.104% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 97.962% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -157.794% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 97.518% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 92.46% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -804.11% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 93.919% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -2962.411% |
| Waters Corporation | 4.62 Billion USD | 56.521% |
| Biogen Inc. | 26.84 Billion USD | 92.506% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1116.851% |
| Evolus, Inc. | 188.99 Million USD | -964.402% |
| Adicet Bio, Inc. | 207.29 Million USD | -870.452% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1498.565% |
| bluebird bio, Inc. | 619.16 Million USD | -224.907% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -877.52% |
| FibroGen, Inc. | 423.52 Million USD | -374.985% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 81.309% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -7015.415% |
| Homology Medicines, Inc. | 47.05 Million USD | -4175.024% |
| Geron Corporation | 394.07 Million USD | -410.485% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 47.474% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -158.613% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -67.823% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -445.93% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -54.63% |
| Zoetis Inc. | 14.28 Billion USD | 85.918% |
| Abeona Therapeutics Inc. | 64 Million USD | -3043.18% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 40.049% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 70.596% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 91.15% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -3495.592% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 32.721% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1115.498% |
| Verastem, Inc. | 149.71 Million USD | -1243.658% |
| Nektar Therapeutics | 398.03 Million USD | -405.41% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -241.988% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -919.071% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 38.378% |
| Exelixis, Inc. | 2.94 Billion USD | 31.63% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 38.128% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -223.675% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1203.031% |
| uniQure N.V. | 831.68 Million USD | -141.881% |
| Imunon, Inc. | 21.91 Million USD | -9078.263% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -91.727% |
| Insmed Incorporated | 1.32 Billion USD | -51.274% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -16.064% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -114.669% |
| TG Therapeutics, Inc. | 329.58 Million USD | -510.369% |
| Incyte Corporation | 6.78 Billion USD | 70.338% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -9.635% |